This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY (CARGOII)

This study has been completed.
Information provided by:
XDx Identifier:
First received: September 26, 2008
Last updated: March 5, 2009
Last verified: March 2009
The Cardiac Allograft Rejection Gene Expression Observational (CARGO) II Study is designed to provide independent evidence of the clinical performance of the non-invasive AlloMap test. Sensitive detection of cardiac allograft rejection and dysfunction is the basis for successful recipient management. The CARGO II Study will assess the correlation between the presence or absence of acute cellular rejection as determined by examination of endomyocardial biopsy specimens with results from the AlloMap Test. Of 17 participating transplant centers, 4 are in North America and 13 are in Europe.

Graft Rejection Heart Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY

Resource links provided by NLM:

Further study details as provided by XDx:

Primary Outcome Measures:
  • Acute Cellular Rejection(ACR)grades - ACR ISHLT Grades will be determined by centralized pathology reading. The associated AlloMap Test score will be correlated to the biopsy reading. [ Time Frame: Scheduled clinic visit ]

Secondary Outcome Measures:
  • Evaluation of the AlloMap Test and novel gene expression algorithm in guiding management of steroids and calcineurin inhibitors based on the algorithm's capacity to predict future cellular rejection and future graft dysfunction. [ Time Frame: more than 2 months following date of transplant ]
  • Assessment of clinical utility of the AlloMap Test and novel gene expression algorithms in diagnosis and prediction of humoral rejection. [ Time Frame: >2 months after date of transplant ]

Biospecimen Retention:   Samples Without DNA
venous blood whole blood white blood cells

Estimated Enrollment: 800
Study Start Date: May 2005
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Heart transplanted subjects.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
New and existing cardiac allograft recipients.

Inclusion Criteria:

  • New and existing allograft recipients
  • All patients (age ≥ 18years) receiving post-transplant care at the enrolling centers

Exclusion Criteria:

  • Concurrent enrollment in a double-blind drug trial (immunosuppressive drugs).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00761787

United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
United States, Texas
Texas Heart Institute
Houston, Texas, United States, 77030
Medizinische Universität Innsbruck, Klinische Abteilung für Herzchirurgie
Anichstrasse 35, Innsbruck, Austria, A-6020
Medical University of Vienna (Medizinische Universität Wien)
Währinger Gürtel 18-20, Vienna, Austria, 1090
UZ Gasthuisberg
Herestraat 49, Leuven, Belgium, 3000
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2N2
Hospital La Pitie
47 Bd de l, Paris, France, 75013
Herz- und Diabeteszentrum NRW
Georgstraße 11, Bad Oeynhausen, Germany, D-32545
Deutsches Herzzentrum Berlin
Augustenburger Platz, Berlin, Germany, 13353
Medizinische Hochschule Hannover
Hannover, Carl-Neuberg-Str. 1, Germany, 30625
UKM - Medizinische Klinik und Poliklinik C (Kardiologie und Angiologie)
Albert-Schweitzer-Str. 33, Münster, Germany, D-48149
Ospedali Riuniti di Bergamo
Largo Barozzi 1, Bergamo, Italy, 24128
Silesian Center for Heart Disease
ul. Szpitalna 2, Zabrze, Poland, 41-800
Hospital Juan Canalejo
As Xubias 84, La Coruna, Spain, 15006
Inselspital - Universitätsspital Bern Postfach 33
Schweizer Herz-und Gefässzentrum Bern, Bern, Switzerland, 3010
United Kingdom
Papworth Hospital
Papworth Everard, Cambridge, United Kingdom, CB3 8RE
Sponsors and Collaborators